A Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of a Zanubrutinib Tablet Compared to Zanubrutinib Capsules and to Evaluate the Effects of Food on the Pharmacokinetics of the Zanubrutinib Tablet
Latest Information Update: 30 Oct 2024
At a glance
- Drugs Zanubrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Lupus nephritis; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; SARS-CoV-2 acute respiratory disease; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors BeiGene
- 27 Jan 2023 Status changed from recruiting to completed.
- 24 Sep 2022 New trial record